Nomura
http://www.nomura.com/Nomura (NYSE: NMR) is a global investment banking and securities firm. The firm’s operations include Domestic Retail, Global Markets, Global Investment Banking, Global Merchant Banking, and Asset Management. Nomura is headquartered in Tokyo, Japan.
Nomura is represented in the Americas by Nomura Holding America (NHA). NHA’s major divisions are Fixed Income, Investment Banking, Equities and Asset Management.
View Older Stories
-
Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Pa
-
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Ca
-
Exelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanc
-
Exelixis' (EXEL) Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX in Combination with OPDIVO as First-Line Treatment for Patients with Advanced RCC
-
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcino
-
Exelixis Announces Positive Findings at ASCO GU for CABOMETYX® (cabozantinib) in Patients with Brain Metastases from Renal Cell Carcinoma
-
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
-
Exelixis (EXEL), Takeda Pharma & Ono Pharma Report Submission of Supplemental Application for CABOMETYX (cabozantinib) in Combination with OPDIVO (nivolumab) in Japan
-
Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Rena
-
Exelixis (EXEL) Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab
-
Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab
-
Exelixis (EXEL) Announces Submission of sNDA to U.S. FDA for CABOMETYX in Combination With Opdivo for Advanced Renal Cell Carcinoma
-
Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX® (cabozantinib) in Combination With Opdivo® (nivolumab) for Advanced Renal Cell
-
Exelixis (EXEL) Begins CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab in Previously Treated Metastatic RCC
-
Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma
-
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma
-
Exelixis (EXEL) Commences Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab
-
Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinom
-
Exelixis (EXEL) Reports Partner, Takeda Pharmaceutical, to File NDA in Japan for CABOMETYX (Cabozantinib) for Advanced RCC
-
Exelixis’ Partner Takeda Announces Filing of New Drug Application in Japan for CABOMETYX® (Cabozantinib) for Advanced Renal Cell Carcinoma
-
Exelixis (EXEL) Highlights Results from Dose-Escalation Stage of Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab
-
Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma
-
Exelixis (EXEL) Highlights Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib
-
Exelixis Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcin
-
Exelixis (EXEL) Partner Ipsen Reports Health Canada’s Approval of CABOMETYX (cabozantinib) Tablets
-
Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma
-
Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma
-
Exelixis (EXEL) Reports New Recommendations for CABOMETYX (Cabozantinib) Tablets in Updated National Comprehensive Cancer Network Clinical Practice Guidelines
-
Exelixis Announces New Recommendations for CABOMETYX® (Cabozantinib) Tablets in Updated National Comprehensive Cancer Network Clinical Practice Guidelines
-
Exelixis (EXEL) Partner Ipsen Reports European Commission Approval of CABOMETYX (Cabozantinib)
-
Exelixis’ Partner Ipsen Announces European Commission Approval of CABOMETYX® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
-
Exelixis (EXEL) Reports Positive CHMP Opinion for CABOMETYX (cabozantinib)
-
Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
-
Exelixis (EXEL) Confirms FDA Approval of CABOMETYX Tablets for Previously Untreated Advanced RCC
-
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
-
Exelixis (EXEL) Granted U.S. FDA Priority Review for CABOMETYX as Treatment for Previously Untreated Advanced Renal Cell Carcinom
-
Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma
-
Exelixis (EXEL) & Ipsen Reports Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib at ESMO 2017
-
Ipsen and Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017
-
Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017
-
Exelixis (EXEL) Submits sNDA for CABOMETYX for Treatment of Previously Untreated Advanced Kidney Cancer
-
Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (cabozantinib) for the Treatment of Previously Untreated Advanced Kidney Cancer
-
Bristol-Myers Squibb (BMY) & Exelis (EXEL) Commence Phase 3 Trial of Opdivo in Combination with CABOMETYX or Opdivo & Yervoy in Combination with CABOMETYX
-
Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Adv
-
Ipsen and its partner Exelixis announce independent radiology committee review confirms results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell
-
Exelixis (EXEL) Reports Independent Radiology Committee Review Confirms Results from CABOSUN, the Phase 2 Trial of Cabozantinib Versus Sunitinib
-
Exelixis Announces Independent Radiology Committee Review Confirms Results from CABOSUN, the Phase 2 Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma
-
Exelixis (EXEL) Announces Statistically Significant Data from Cabozantinib Phase 2 in RCC
-
Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016
-
Ipsen and Its Partner Exelixis Announce Positive Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at the European Soc